Chiroscience Group - Re Directorate
July 01 1997 - 4:39AM
UK Regulatory
RNS No 7605n
CHIROSCIENCE GROUP PLC
1st July 1997
CHIROSCIENCE ANNOUNCES CHANGES
TO R&D RESPONSIBILITIES
Chiroscience announces today the appointment of Dr Robert
Jackson as Executive Director for Research and
Development for its Darwin Discovery activities in the
UK. Dr Jackson will be based in Cambridge, UK, and will
report to Dr John Padfield, Chief Executive of
Chiroscience Group plc, alongside Dr David Galas,
Executive Director for Discovery Research for Darwin
Discovery activities in the USA.
Dr Jackson joins Chiroscience from Agouron where he was
Vice President for Research and Development. Agouron is
a major US biotechnology company with one of the leading
R&D pipelines in the industry. Its first drug, for which
Dr Jackson was responsible, has just been launched.
Prior to joining Agouron in 1992, Dr Jackson held senior
industrial positions in Du Pont Merck and Warner-Lambert
over a 10 year period and academic positions in Indiana
University, Scripps Clinic and the University of London
Institute of Cancer Research.
Bob Jackson is 54 and was educated in Cambridge and
London before conducting post-doctoral research at Yale
University School of Medicine. He is well recognised
within the cancer field and has published widely,
including research on matrix metalloproteinases.
Dr Jackson will be responsible for all biological and
chemical research and development, technical operations
and clinical development activities in Cambridge and
Stevenage.
Dr Jon Dickens, who has been responsible for the pre-
clinical research activities in Cambridge, has indicated
his wish to leave Chiroscience to pursue other interests.
He will act as a consultant to the Group on defined
projects.
Commenting, Dr John Padfield, Chief Executive of
Chiroscience said, 'The growth in our applied research
programmes, particularly in the exploitation of our
investment in enzyme inhibitors through their development
for a number of clinical end points, requires their
leadership and co-ordination through one director. Bob
Jackson's experience and record make him an ideal
candidate for this role and I am delighted he has joined
us. Jon Dickens has played a key role in research in
helping Chiroscience reach this point. We wish him all
success in his future career.'
For further information please contact:
Dr John Padfield, Chief Executive Matthew Hooper/Sarah Carrell
Chiroscience Group plc Shandwick Consultants
Tel: 01223 420430 Tel: 0171 329 0096
END
Amedeo Res (LSE:AMED)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amedeo Res (LSE:AMED)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Amedeo Res (London Stock Exchange): 0 recent articles
More Chiroscience Group News Articles